FILANA THERAPEUTICS, INC.
FLNAFilana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam (previously known as PTI-125 and sumifilam), an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
5wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How FLNA's past catalysts played out
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is FILANA THERAPEUTICS, INC.'s next FDA catalyst?→
FILANA THERAPEUTICS, INC.'s (FLNA) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track FLNA biotech catalysts?→
Add FLNA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow FILANA THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.